Detalhe da pesquisa
1.
Real world study of safety and efficacy of lorlatinib as second line and beyond in ALK-rearranged advanced non-small cell lung cancer patients in India - a multicentre chart review study (ROSELAND).
Ecancermedicalscience
; 18: 1667, 2024.
Artigo
Inglês
| MEDLINE | ID: mdl-38439810